In India, there are roughly 30 million heart patients and two Lac surgeries are being performed every year. YOSPRALA-a new emerging drug approved by USFDA in September 2016 to treat Ischemic stroke, prophylaxis and gastric ulcer prophylaxis. The active ingredients present are Aspirin and Omeprazole. Hence an attempt is made to develop a new analytical method for Simultaneous estimation of Aspirin and Omeprazole using methanol as solvent The Absorption maxima of Aspirin and Omeprazole was at 224nm and 251.8nm respectively. Linearity range for aspirin was 0.5-25µg/ml with regression co-efficient-099 and omeprazole was 1-8µg/ml with regression coefficient 0.992. The method was validated for precision and % RSD was less than 1.5% for both aspirin and omeprazole. The proposed method was statistically validated for standard deviation, relative standard deviation, coefficient of variance and the results were within the limits. Hence the above method was simple, cost effective, robust and can be used for routine analysis in pharmaceutical preparations.
INTRODUCTION
YOSPRALA is designed to support both cardio and gastro protection for at risk patients through proprietary intell-coat system, which is formulated to sequentially deliver immediate release of Omeprazole(40mg)followed by a delayed release ,enteric coated aspirin core either in (81mg) or 325mg dose strength. 1 Yosprala is approved by USFDA on September 1 4th 2016 as a cardiovascular and cerebrovascular drug. 2 An extensive literature survey reveals that there is no analytical method yet reported for simultaneous estimation of aspirin and omeprazole in combination by any analytical techniques. There are methods been developed for estimation of aspirin individually 3 , in combination with other drugs by UV Spectroscophy in tablet dosage form [4] [5] [6] , by RP-HPLC in bulk 7 and in tablet dosage form 8 , by HPTLC in bulk and synthetic mixtiure 9. Whereas methods been developed for estimation of Omeprazole capsules individually10 -11 , bioanalysis of omeprazole by LC-MS/MS 12 in combination with other drugs by RP-HPLC in bulk and capsule [13] [14] , in tablet dosage dorm 15 , by NP-HPLC 16 . Hence an attempt was made to develop a simple and cost effective method for simultaneous estimation of aspirin and omeprazole and the proposed methods was validated according to ICH guidelines.
MATERIALS AND METHODS:
The reference standard of standard Aspirin (99%purity) and omeprazole (99%purity) were purchased from 
1) Instrument employed:
The instrument employed for the study was as follows. 2) Solubility studies: The solubility studies performed using various solvents are listed below. 10ml of above solution is taken and made up to 100ml with Methanol in 100ml standard flask which gives 100µg/ml.
Stock solution of Omeprazole
50mg of Omeprazole standard was dissolved in 50 ml of methanol in 50ml standard flask which gives 1000µg/ml.
10ml of above solution is taken and made up to with Methanol in 100ml standard flask which gives 100µg/ml. 
RESULTS & DISCUSSION: 1) System suitability parameters:
The following parameters are system suitability parameters for the analytical method developed according to ICH guidelines. 2) Validation of proposed method:
2.1) Linearity:
It is an analytical procedure is its ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in the sample. According to ICH guidelines acceptance criteria for precision the %RSD should NMT 2%
2.1.1: For Aspirin:

2.3) Statistical validation:
The proposed method was statistically validated for the following parameters and was within the Acceptance criteria as per ICH guidelines. 
2.4) Ruggedness and Robustness:
An analytical procedure is a measure of its capacity to remain unaffected by small, deliberate variations in method parameters and provides an indication of its reliability during normal usage. 
2.4.1: Ruggedness:
